Pages that link to "Q28250560"
Jump to navigation
Jump to search
The following pages link to Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment (Q28250560):
Displaying 50 items.
- DREADDs: novel tools for drug discovery and development (Q26995396) (← links)
- Structural Features for Functional Selectivity at Serotonin Receptors (Q27676930) (← links)
- Comprehensive characterization of the Published Kinase Inhibitor Set (Q27702518) (← links)
- Improving Treatment of Erythematotelangiectatic Rosacea with Laser and/or Topical Therapy Through Enhanced Discrimination of its Clinical Features (Q28077479) (← links)
- Echocardiographic evidence for valvular toxicity of benfluorex: a double-blind randomised trial in patients with type 2 diabetes mellitus (Q28480527) (← links)
- Structure and function of serotonin G protein-coupled receptors. (Q30382524) (← links)
- Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs (Q33536988) (← links)
- Structural basis for μ-opioid receptor binding and activation (Q34073218) (← links)
- Drug-induced valvulopathy: an update (Q34131760) (← links)
- Methylphenidate off-label use and safety (Q34172165) (← links)
- Serotonin receptors and heart valve disease--it was meant 2B. (Q34173511) (← links)
- Neurochemical profiles of some novel psychoactive substances (Q34319162) (← links)
- Identification of novel functionally selective κ-opioid receptor scaffolds (Q34376764) (← links)
- Potential drug targets for calcific aortic valve disease. (Q34399089) (← links)
- Aortic valve cyclic stretch causes increased remodeling activity and enhanced serotonin receptor responsiveness (Q35250865) (← links)
- Functional Annotation Analytics of Rhodopseudomonas palustris Genomes (Q35447258) (← links)
- Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily (Q35671396) (← links)
- Design and Synthesis of (2-(5-Chloro-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)cyclopropyl)methanamine as a Selective Serotonin 2C Agonist (Q35776457) (← links)
- We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders. (Q35823591) (← links)
- Serotonin and blood pressure regulation (Q35847080) (← links)
- Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs (Q36223175) (← links)
- Regulatory Forum Review*: Utility of in Vitro Secondary Pharmacology Data to Assess Risk of Drug-induced Valvular Heart Disease in Humans: Regulatory Considerations (Q36350604) (← links)
- Use of decongestants during pregnancy and the risk of birth defects (Q37276210) (← links)
- Chemical-protein interactome and its application in off-target identification (Q37849214) (← links)
- Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. (Q38063789) (← links)
- Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs (Q38167630) (← links)
- Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy (Q38173201) (← links)
- Adverse effects of benfluorex on heart valves and pulmonary circulation (Q38211003) (← links)
- Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents (Q38219851) (← links)
- Serotonin and catecholamines in the development and progression of heart valve diseases. (Q38634250) (← links)
- Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014). (Q38648544) (← links)
- Atypical sympathomimetic drug lerimazoline mediates contractile effects in rat aorta predominantly by 5-HT2A receptors (Q41598101) (← links)
- Ligand functional selectivity advances our understanding of drug mechanisms and drug discovery (Q41922335) (← links)
- A new serotonin 5-HT6 receptor antagonist with procognitive activity - Importance of a halogen bond interaction to stabilize the binding. (Q42328355) (← links)
- Tourette's Disorder. (Q42907007) (← links)
- Inflammatory aneurysm of the abdominal aorta in a patient treated with ropinirole (Q43091044) (← links)
- Crystal Structure of an LSD-Bound Human Serotonin Receptor (Q46266293) (← links)
- Discovery of new GPCR ligands to illuminate new biology (Q46344527) (← links)
- Molecular Connectivity Predefines Polypharmacology: Aliphatic Rings, Chirality, and sp3 Centers Enhance Target Selectivity (Q47163647) (← links)
- Comprehensive review of cardiovascular toxicity of drugs and related agents. (Q47556269) (← links)
- Inhibition of 5-Hydroxytryptamine Receptor 2B Reduced Vascular Restenosis and Mitigated the β-Arrestin2-Mammalian Target of Rapamycin/p70S6K Pathway (Q47639140) (← links)
- 5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology. (Q49344600) (← links)
- In Vitro Safety Pharmacology Profiling of Topical α-Adrenergic Agonist Treatments for Erythema of Rosacea. (Q49642435) (← links)
- Structural determinants of 5-HT2B receptor activation and biased agonism (Q57480416) (← links)
- Comments on: "In Vitro Safety Pharmacology Profiling of Topical α-Adrenergic Agonist Treatments for Erythema of Rosacea" (Q58800387) (← links)
- Pathological Conditions Associated with the Disturbance of the 5-HT System (Q59201274) (← links)
- Benfluorex: the last chapter of drug-induced valvular heart disease? (Q83069848) (← links)
- Dibenzofuranylethylamines as 5-HT2A/2C Receptor Agonists (Q89738216) (← links)
- Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68) (Q91822932) (← links)
- Drug-associated valvular heart diseases and serotonin-related pathways: a meta-analysis (Q92298043) (← links)